Landing
Society of Hematologic Oncology (SOHO) 2022
Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
Normalization of Hematologic Markers and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan and Baseline Hemoglobin at or Above 10 g/dL
Pegcetacoplan Rapidly Stabilizes Complement Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria Experiencing Hemolysis with Acute Hemoglobin Decreases: PRINCE Trial Post Hoc Analysis
A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial Data vs Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria
Rapid Time to a Clinically Meaningful Response in FACIT-Fatigue Scores with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Kaplan-Meier Analysis from the PEGASUS Trial
Mixed-Methods Study Assessing the Impact of C3 Inhibition on the Emotional and Physical Burden of Living with Paroxysmal Nocturnal Hemoglobinuria (PNH)
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.